

# Epinephrine use in cardiac arrest

Jae Hyuk Lee, MD, PhD

Department of Emergency Medicine+

Seoul National University Bundang Hospital

# Epinephrine



Most commonly used drug during cardiopulmonary resuscitation



# Epinephrine (Adrenaline)

- Hormone, Neurotransmitter, Medicine
- Produce : Adrenal gland, Neurons, synthesized
  - Function : Fight-or-flight response & hyperarousal, acute stress response
- Receptors :  $\alpha$  &  $\beta$  adrenergic receptors
- Adrenal gland extract
  - ***Pellacani***, 1874
    - first administration of adrenal gland extract to animals
  - ***Napoleon Cybulski***, 1875
    - first isolation of adrenal gland extract
  - ***Abel*** (US) named epinephrine (1899) / ***Takamine*** (Europe) named adrenaline (1901)



# Historical considerations of epinephrine in cardiac resuscitation

- ***George Crile & David H. Dolley***, 1906, J Exp Med
  - asphyxial cardiac arrest of dogs
    - Adrenaline : markedly more successful in resuscitation
    - noted the importance of an adequate aortic diastolic pressure
      - ***coronary pressure*** : 30-40mmHg



- **Cardiovascular effect of epinephrine (adrenaline)**

Heart ( $\beta$ 1 receptors)	$\uparrow$ heart rate	$\uparrow$ contractility	$\uparrow$ heart work & O <sub>2</sub> consumption
Blood vessels ( $\alpha$ & $\beta$ 2 receptors)	Vasoconstriction of blood vessels of skin and mucous membrane ( $\alpha$ -stimulation)	vasodilation of the skeletal muscles and coronary blood vessels ( $\beta$ 2-stimulation)	

- **Effect of epinephrine during CPR**

**Inotropic and chronotropic effects**

**VS.**

**Peripheral vasoconstriction**  
 $\uparrow$  Diastolic aortic pressure  $\rightarrow$   $\uparrow$  perfusion to the heart



- **Redding & Pearson, 1963, Anesthesiology**
- Asphyxia cardiac arrest in dogs


Drugs	ROSC rate
<b>Epinephrine (non-selective)</b>	<b>10/10</b>
Phenylephrine ( $\alpha_1$ selective)	9/10
Isoproterenol ( $\beta_1, \beta_2, \beta_3$ )	0/10
metaraminol ( $\alpha_1 > \beta$ )	9/10
Methoxamine ( $\alpha_1$ selective)	9/10
Mephentermine ( $\alpha_1, \alpha_2, \beta_1$ )	3/10
Calcium chloride	6/10

- **Yakaitis RW et al. 1979, Crit Care Med**

	Group A	Group B	Group C
Drug treatment	Phenoxybenzamine ( $\alpha$ blocker) + isoproterenol ( $\beta$ agonist)	Propranolol ( $\beta$ blocker) + Phenylephrine ( $\alpha_1$ agonist)	Epinephrine
ROSC	ROSC 3/11	ROSC 10/10	ROSC 10/10
Mean diastolic pressure	10mmHg	38mmHg	40mmHg




- **Return of spontaneous circulation**
  - Depends on adequate coronary perfusion pressure
  - $CPP = \text{diastolic aortic pressure} - LVEDP$



# Epinephrine (Adrenaline)


- **Effect during cardiac arrest**

	$\alpha$ -adrenergic effect	$\beta$ -adrenergic effect
Beneficial	$\uparrow$ Coronary perfusion pressure	Vasodilation of coronary blood vessels → increase coronary blood flow
Harmful	Platelet activation → thrombosis → impairs microvascular blood flow	$\uparrow$ myocardial work & O <sub>2</sub> consumption $\downarrow$ subendocardial perfusion



- C57BL/6 Mouse
- Post-cardiac arrest
- Brain capillary

Blood clot



- LysM<sup>GFP/+</sup> Mouse
- Post-cardiac arrest
- Brain capillary

Blood clot

# Recommendation of epinephrine in cardiopulmonary resuscitation

- **2015 AHA guidelines**

- Standard-dose epinephrine (1mg every 3 to 5 minutes) may be reasonable for patients in cardiac arrest (Class IIb, LOE B-R)

- **For VF/pVT : after 2 defibrillation attempts**

- For non-VF/pVT : as soon as IV/IO access is achieved

- **2015 ERC guidelines**

- 1mg every 3-5 minutes

- **For VF/pVT : after 3 defibrillation attempts**

- For non-VF/pVT : as soon as IV/IO access is achieved



## **Administration of epinephrine during CPR is beneficial ?**

Epinephrine : as a pressor to increase coronary perfusion pressure  
during chest compression



# Survival Outcomes With the Introduction of Intravenous Epinephrine in the Management of Out-of-Hospital Cardiac Arrest

*Ann Emerg Med, 2007*

- Singapore
- Before and After study
  - Introduction of IV epinephrine in prehospital phase
- 1,296 OHCA patients
  - Pre-epinephrine (n=615) vs. Epinephrine (n=681)

	Pre-epinephrine (n=615)	Epinephrine (n=681)
ROSC	110 (17.9%)	107 (15.7%)
Survival to hospital admission	46 (7.5%)	51 (7.5%)
Survival to discharge	6 (1.0%)	11 (1.6%)

**Epinephrine use : no survival benefit**



# Intravenous Drug Administration During Out-of-Hospital Cardiac Arrest

- A Randomized Trial

JAMA, 2009

- Norway
- adults (>18years), non traumatic OHCA
- evaluate IV access and drug administration during Prehospital ACLS
- 851 patients randomized

	No IV group (n=433)	IV group (n=418)
IV drug during CPR	42 (10%)	343 (82%)
Epinephrine	37 (9%)	330 (79%)
Atropine	20 (5%)	194 (46%)
Amiodarone	17 (4%)	69 (17%)
Outcomes		
Any ROSC	107 (25%)	165 (40%)
Hospital admission	126 (29%)	178 (43%)
Survival to discharge	40 (9.2%)	44 (10.5%)
Good neurological outcome at discharge	35 (8.1%)	41 (9.8%)
1-yr survival	36 (8%)	41 (10%)

Intravenous drug during ACLS: ↑ short-term survival, but not survival to discharge



# PACA (Prehospital Adrenaline in Cardiac Arrest) trial

*Resuscitation, 2011*

- Western Australia, Perth
- Randomized double blind placebo-controlled trial
  - Adrenaline vs. placebo
- Sample size = 2,213 per group
  - 601 victims randomized



	Placebo, n=262	Adrenaline, n=272
pre-hospital ROSC	22 (8.4%)	64 (23.5%)
Hospital admission	34 (13.0%)	69 (25.4%)
Survival to discharge	5 (1.9%)	11 (4.0%)
Good neurological outcome	5 (100%)	9 (81.8%)

use of adrenaline in cardiac arrest :  prehospital ROSC

Study ended prematurely (enrolled 10 % of the intended)



# Prehospital epinephrine Use and Survival Among Patients With Out-of-Hospital Cardiac arrest

JAMA, 2012

- Japan
- Prospective observational Propensity analysis using national registry
- Adult OHCA patients
- Study period: 2005.1 ~ 2008.12
  - IV access by EMT since 2004
  - IV epinephrine by EMT since 2006
- 417,188 cases
- Propensity score matching
  - Epinephrine vs. No epinephrine (n=13,401 per group)

	Epinephrine (n=13,401)	No epinephrine (n=13,401)
prehospital ROSC	2446 (18.3%)	1400 (10.5%)
1-month survival	687 (5.1%)	944 (7.0%)
Good neurological outcome	173 (1.3%)	413 (3.1%)

**Epinephrine use : improved ROSC, but not 1-month survival  
& resulted in poor neurological outcome**




# PARAMEDIC2 trial

*N Engl J Med, 2018*

- UK
- multi center randomized double-blind placebo controlled trial
- prehospital ACLS
  - epinephrine vs. placebo
- Study period : 2014.12~2017.10
- 8,016 patients randomized

	Epinephrine (n=4,015)	Placebo (n=3,999)
Prehospital ROSC	1457/4015 (36.3%)	468/3999 (11.7%)
30-day survival	130/4012 (3.2%)	94/3995 (2.4%)
hospital admission	947/3973 (23.8%)	319/3982 (8.0%)
survival to discharge	128/4009 (3.2%)	91/3995 (2.3%)
Good neurological outcome at discharge	87/4007 (2.2%)	74/3994 (1.9%)
3-month survival	121/4009 (3.0%)	86/3991 (2.2%)
Good neurological outcome at 3mo	82/3986 (2.1%)	63/3979 (1.6%)



**Epinephrine: ↑ survival, but not favorable neurological outcome**

Survival with a favorable neurological outcome at hospital discharge



## **Epinephrine during CPR**



**Increase coronary perfusion pressure → increase chance of ROSC**

**Increase cerebral blood flow during CPR ?**



# Epinephrine reduces cerebral perfusion during CPR

*Crit Care Med, 2009*




**Epinephrine decreased cerebral microcirculation during post-resuscitation phase**

# Effects of epinephrine on cerebral oxygenation during cardiopulmonary resuscitation: A prospective cohort study

*Resuscitation, 2016*

- Study period : 2011.8~2014.9
- adult IHCA (n=36)
- Using Cerebral oximetry (Equanox 7600, Nonin Medical, USA)





**1mg epinephrine : small, but insignificant increase in rSO<sub>2</sub>**



# Study of the Effects of Epinephrine on Cerebral Oxygenation and Metabolism During Cardiac Arrest and Resuscitation by Hyperspectral Near-Infrared Spectroscopy

Crit Care Med, 2018

- Swine cardiac arrest model
- Placebo vs. Epi bolus (0.015mg/kg every 4 min) vs. Epi continuous (0.045mg/kg over 12min)



## Carotid blood flow

Epinephrine bolus : no significant change in carotid blood flow, but transient improvement of cerebral metabolism



# Adequate dose of epinephrine

**Standard dose (1mg) vs. High dose (0.1~0.2mg/kg) vs. Low dose (0.5mg)**





## Standard vs. High dose

# The Effect of Standard- and High-Dose Epinephrine on Coronary Perfusion Pressure During Prolonged Cardiopulmonary Resuscitation

*JAMA, 1991*

- Prospective cross-over design
- 32 patients who were in prolonged cardiac arrest
- Epinephrine 1mg vs. 0.2mg/kg



**High dose epinephrine increased CPP in prolonged CPR, but standard dose did not**

# Standard vs. High dose

## A Randomized Clinical Trial of High-Dose Epinephrine and Norepinephrine vs Standard-Dose Epinephrine in Prehospital Cardiac Arrest

JAMA, 1992

- US
- Prehospital cardiac arrest
- 816 patients
- High dose epinephrine (15mg) vs. Norepinephrine (11mg) vs. Standard-dose epinephrine (1mg)

	High dose epinephrine (n=286)	Standard dose epinephrine (n=270)	Norepinephrine (n=260)
Prehospital ROSC	37 (13%)	22 (8%)	35 (13%)
Hospital admission	30 (10%)	21 (8%)	27 (10%)
Survival to discharge	5 (1.7%)	3 (1.2%)	7 (2.6%)
Good neurological outcome	0 (0%)	2 (0.7%)	0 (0%)

**High dose epinephrine : increased ROSC & hospital admission  
, but not hospital discharge and good neurological outcome**



## High dose epinephrine in adult cardiac arrest

*N Engl J Med, 1992*

- **Canada**
- **Randomized controlled trial**
- **IHCA and OHCA (n=650)**
- **High dose (7mg) vs Standard dose (1mg) every 5 minutes**
- **Study period : 1989.12~1992.1**

	High dose (n=317)	Standard dose (n=333)
Resuscitated	56 (18%)	76 (23%)
Discharged	10 (3%)	16 (5%)
Good CPC	9 (90%)	15 (94%)

**High dose epinephrine : no benefit on the survival and neurological outcome**



## A comparison of standard-dose and high-dose epinephrine in cardiac arrest outside the hospital

*N Engl J Med, 1992*

- US
- Randomized controlled trial
- OHCA (n=1280)
- Prehospital ACLS
- epinephrine 0.2mg/kg vs. 0.02mg/kg

	High dose (n=648)	Standard dose (n=632)
ROSC	217 (33%)	190 (30%)
Hospital admission	145 (22%)	136 (22%)
Survival to discharge	31 (5%)	26 (4%)
Conscious at discharge	29 (94%)	24 (92%)

**No difference in outcomes**



# Standard doses versus repeated high doses of epinephrine in cardiac arrest outside the hospital

*Resuscitation, 1995*

- France
- Study period : 1991.1~1992.7
- OHCA (n=536)
- Randomized controlled trial
- Epinephrine 1mg vs 5mg every 5 minutes

	High dose	Standard dose
ROSC	96 (35.5%)	85 (32%)
Hospital admission	65 (24%)	54 (20.4%)
Neurological outcome	no difference	

**No difference in outcomes**



# A comparison of repeated high doses and repeated standard doses of epinephrine for cardiac arrest outside the hospital

*N Engl J Med, 1998*

- France and Belgium
- Multicenter Randomized trial
- OHCA (n=3327)
- Epinephrine 1mg vs 5mg every 5 minutes

	High dose (n=1677)	Standard dose (n=1650)
ROSC	678 (40.4%)	601 (36.4%)
Hospital admission	444 (26.5%)	389 (23.6%)
Survival to discharge	38 (2.3%)	46 (2.8%)
Neurological outcome	no difference	


**high dose epinephrine : improved ROSC and hospital admission,  
but not long-term survival and neurological outcome**



# Lower-dose epinephrine administration and out-of-hospital cardiac arrest outcomes

- US
- OHCA
- Before and After study
  - Before period : 2008.1~2012.9
    - Shockable 1mg at 4 min then 1mg every 8min
    - Non-shockable 1mg every 2min
  - After period : 2012.10~2016.6
    - Shockable 0.5mg at 4 min and 8 min, then 0.5mg every 8 min
    - Non-shockable 0.5mg every 2 min

*Resuscitation, 2018*



**Lower dose epinephrine : not associated with a change in survival and neurological outcome**




**Optimal dosing interval ? Not known yet**



# Adrenaline (epinephrine) dosing period and survival after in-hospital cardiac arrest: A retrospective review of prospectively collected data

*Resuscitation, 2014*

- US
- GWTG-Resuscitation registry (National Registry of CPR)
- Study period : 2000.1~2009.11
- 20,909 patients




**Less frequent dosing of epinephrine was associated with improved survival**

# The influences of adrenaline dosing frequency and dosage on outcomes of adult in-hospital cardiac arrest: A retrospective cohort study

*Resuscitation, 2016*

- Taiwan
- National Taiwan University Hospital
- IHCA (n=896)
- Study period: 2006~2012



**Higher dosing frequency : lower rates of survival and favorable neurological outcomes**




**Time to first epinephrine**

**OHCA vs. IHCA  
Shockable vs. Non-shockable**



# Epinephrine Improves 24-Hour Survival in a Swine Model of Prolonged Ventricular Fibrillation Demonstrating that Early Intraosseous Is Superior to Delayed Intravenous Administration

*Anesth Analg, 2011*



	ROSC	24 hour survival	24 hour neurologically intact survival
IO epinephrine	100%	100%	60%
IV epinephrine	90%	40%	30%

**Effectiveness of epinephrine decreased over time**



# Association between timing of epinephrine administration and intact neurologic survival following out-of-hospital cardiac arrest in Japan: A population-based prospective observational study

*Acad Emerg Med, 2012*

- Japan
- Retrospective analysis
- adult, witnessed OHCA, Prehospital setting
- 49,165 patients
  - Cardiac cause (n=33,163)
  - Non-cardiac cause (n=16,002)
- Early epinephrine (<10min) vs. Delayed epinephrine (>10min)

	Cardiac cause		Non-cardiac cause	
	Early epi (n=1762)	Delayed epi (n=31401)	Early epi (n=639)	Delayed epi (n=15363)
Survival	199 (11.3%)	1877 (6.0%)	44 (6.9%)	561 (3.7%)
Intact neurologic survival (CPC 1-2)	80 (4.5%)	812 (2.6%)	8 (1.3%)	93 (0.6%)

**Early epinephrine : associated with intact neurologic survival**



# Rapid epinephrine administration improves early outcomes in out-of-hospital cardiac arrest

*Resuscitation, 2013*

- US
- Retrospective analysis
- Adult OHCA
- Study period : 2005.11~2011.4
- 686 patients analyzed
  - Epinephrine < 10 min vs. >10min

	Epi < 10min	Epi > 10min
All patients	n=155	n=531
prehospital ROSC	51 (33%)	124 (23%)
Survival to discharge	8/150 (5.3%)	19/514 (3.7%)
Shockable	n=47	n=123
prehospital ROSC	20 (43%)	38 (31%)
Survival to discharge	6 (13%)	11 (9.2%)
Non-shockable	n=107	n=406
prehospital ROSC	31 (29.0%)	85 (20.9%)
Survival to discharge	2 (1.9%)	8 (2.0%)


**Early administration of epinephrine improved rates of ROSC, but not survival to discharge**



# The time dependent association of adrenaline administration and survival from out-of-hospital cardiac arrest

*Resuscitation, 2015*

- US
- Retrospective analysis of Save Hearts in Arizona Registry and Education (SHARE) database
- Study period : 2005.1~2013.11
- Witnessed arrest (n=3,469)
  - Shockable (n=1,451), Non-shockable (n=2,018)




**Early administration of epinephrine : associated with survival to discharge, but not with good neurological outcome**

# Time to Epinephrine Administration and Survival From Nonshockable Out-of-Hospital Cardiac Arrest Among Children and Adults

*Circulation, 2018*

- North America
- Retrospective analysis of Resuscitation Outcome Consortium database
- Study period : 2011.6~2015.6
- Non-shockable OHCA (n=32,101)
  - epinephrine < 10min (n=12,238) vs. >10min (n=14,517) vs. no epinephrine (n=5,346)

	Epi < 10min	Epi > 10min
Survival to discharge	2.6%	1.7%




**Delay in administration of epinephrine decreased survival to discharge in non-shockable OHCA patients**

# Time to administration of epinephrine and outcome after in-hospital cardiac arrest with non-shockable rhythms: retrospective analysis of large in-hospital data registry

*BMJ, 2014*

- US
- Retrospective analysis of GWTG-R registry
- Study period : 2000.1~2009.11
- Non-shockable IHCA (n=25,095)



**Earlier administration of epinephrine associated with better survival to discharge**



# Early administration of epinephrine in patients with cardiac arrest with initial shockable rhythm in hospital: propensity score matched analysis

BMJ, 2016

- US
- Retrospective analysis of GWTG-R registry
- Study period : 2006.1~2012.9
- shockable IHCA (n=2,974)
  - Epinephrine (n=1,510) vs No epinephrine (n=1,464) within 2 min after first defib.



**Early administration of epinephrine : associated with decreased chance of good outcomes**

# Hospital Variation in Time to Epinephrine for Nonshockable In-Hospital Cardiac Arrest

*Circulation, 2016*

- US
- Retrospective analysis of GWTG-R registry
- Non-shockable IHCA
  - n=103,932 patients at 548 hospitals
- Epinephrine < 5min vs. >5 min (delayed)
  - Hospitals Stratified by rates of delayed administration of epinephrine

**Table 3.** Outcomes, by Quartiles of Delayed Epinephrine Use

Hospital Characteristics	Q1	Q2	Q3	Q4	P Value (trend)
Unadjusted hospital-level survival, median (%)					
To discharge (interquartile range)	12.0 (8.7–15.6)	11.3 (7.8–15.9)	11.6 (7.4–15.2)	8.1 (5.6–12.8)	<0.0001
With CPC 1 or 2	6.6 (3.0–10.0)	6.4 (3.2–8.9)	6.2 (3.2–9.7)	5.3 (0–7.8)	0.0026
Hospital risk-standardized survival, median (%)					
To discharge	12.9 (11.1–15.4)	12.3 (10.4–15.7)	12.4 (10.5–14.7)	10.8 (9.7–12.7)	<0.0001
With CPC 1 or 2	8.3 (5.1–12.0)	8.0 (5.2–11.0)	7.4 (4.9–11.1)	6.6 (5.0–8.6)	0.0032

CPC indicates cerebral performance category score; Q1–Q4, hospital quartiles for proportion of patients with delayed epinephrine use: Q1 (0%–9.5%), Q2 (9.5%–13.5%), Q3 (13.5%–19.0%), and Q4 (19.0%–53.8%).

**Hospitals of high rates of delayed epinephrine administration had worse survival outcomes**



# Summary

## Epinephrine

- **Efficacy** : good for heart, but not for brain
- **Optimal dose** : Standard dose > High dose
  - low dose : inconclusive
- **Frequency** : less frequent may be better
- **Timing**
  - variable benefit
    - OHCA - early administration a/w increased survival to discharge
    - IHCA, shockable - early administration : not a/w good outcomes
    - IHCA, nonshockable - early administration : a/w good outcomes



- **First priority of CPR : *ROSC* !**
  - **No valuable other option for increasing coronary perfusion pressure during closed chest compression**
- **Need research on other modality to improve neurological outcomes**

